Management of Localized Breast Cancer

Breast Cancer Management and Treatment Introduction The treatment of breast cancer depends critically on the stage of disease at diagnosis, as well as the tumor's molecular characteristics—particularly hormone-receptor status (estrogen and progesterone receptors) and HER2 status. Treatment decisions also consider patient factors such as age, menopausal status, and preferences. This section covers the management of early-stage (localized) disease and metastatic disease, emphasizing how molecular subtype guides therapy selection. Treatment of Early-Stage (Localized) Breast Cancer Surgical Options For most patients with early-stage breast cancer, surgery is the first step in treatment. Two main surgical approaches exist, and the choice depends on tumor size, location, number of tumors, and patient preference. Breast-conserving surgery (lumpectomy) removes the tumor along with a margin of surrounding healthy tissue, preserving most of the breast. This approach is appropriate for most early tumors and offers patients cosmetic and psychological benefits of breast preservation. Importantly, lumpectomy must be followed by radiation therapy to reduce the risk of local recurrence in the treated breast. When radiation is delivered after lumpectomy, whole-breast irradiation typically reduces local recurrence rates to approximately 5%. Total mastectomy removes the entire breast tissue and is chosen when: The tumor is large relative to breast size or multifocal (present in multiple locations) Radiation therapy is contraindicated (for example, in pregnant patients or those with prior chest radiation) The patient prefers this approach for personal reasons Mastectomy alone (without radiation) is sufficient for many early-stage cases, though radiation may be added if there are additional risk factors, such as involved lymph nodes. Sentinel lymph-node biopsy is the standard method for assessing whether cancer has spread to the axillary (underarm) lymph nodes. This procedure identifies the first lymph node(s) that drain from the tumor—the sentinel node(s)—and removes them for pathological examination. If the sentinel node is free of cancer, further lymph-node dissection is typically avoided, minimizing arm swelling and other morbidity associated with removing multiple nodes. This approach maintains accurate staging while reducing complications. Radiation Therapy Radiation therapy is a cornerstone of breast-conserving therapy. After lumpectomy, whole-breast irradiation is delivered to reduce the risk of local recurrence. In high-grade tumors, a radiation "boost" to the tumor bed provides additional benefit. Post-mastectomy radiation is less frequently used but is indicated for certain high-risk features, such as large tumors, involvement of multiple lymph nodes, or close/positive surgical margins. When used, post-mastectomy radiation targets the chest wall and any involved regional lymph-node areas. Radiation is typically administered five days per week for up to seven weeks using external-beam techniques. Brachytherapy (internal radiation) is an alternative approach in selected patients. Systemic Therapies Systemic therapies—chemotherapy, endocrine therapy, and HER2-targeted therapy—treat cancer that may have already spread microscopically beyond the breast and regional lymph nodes. The decision to use systemic therapy and the choice of agents depend on prognostic factors and tumor biology. Chemotherapy Adjuvant chemotherapy (given after surgery) is offered to patients at higher risk of recurrence, particularly those with: Node-positive disease High-risk node-negative disease (determined by tumor grade, size, and other factors) Common chemotherapy regimens combine agents such as cyclophosphamide, doxorubicin (an anthracycline), fluorouracil, docetaxel, and paclitaxel (taxanes). A typical course consists of 4–6 cycles given every 2–3 weeks. For HER2-negative cancers, anthracycline-taxane combinations are widely used because they offer superior outcomes compared to single-agent regimens. Endocrine Therapy Hormone-receptor-positive breast cancers depend on estrogen signaling for growth. Endocrine therapy blocks this pathway and is given for at least five years (sometimes up to ten years) after surgery. Tamoxifen is a selective estrogen-receptor antagonist given for five years to premenopausal women. It blocks the tumor's access to estrogen without lowering the body's estrogen levels. Aromatase inhibitors (anastrozole, letrozole, exemestane) are preferred for postmenopausal women. These agents lower estrogen production by inhibiting the enzyme aromatase, which catalyzes the final step of estrogen synthesis in postmenopausal women. Gonadotropin-releasing hormone (GnRH) agonists (goserelin, leuprolide, triptorelin) suppress ovarian function and are sometimes used in premenopausal women, either alone or in combination with tamoxifen or an aromatase inhibitor. The choice between these agents depends on menopausal status and individual tolerance, since different agents carry different side-effect profiles. HER2-Targeted Therapy Trastuzumab is a monoclonal antibody that targets HER2 and is standard treatment for HER2-positive early-stage tumors. It is typically given for one year (often weekly or every three weeks) and substantially improves survival when combined with chemotherapy. Pertuzumab, another HER2-targeted agent, may be added for high-risk HER2-positive disease, providing additional benefit. Breast Reconstruction Patients who undergo mastectomy may choose breast reconstruction to restore breast appearance. Reconstruction can be performed at the same time as mastectomy or delayed to a later date. Options include: Implant-based reconstruction using silicone or saline implants Autologous tissue transfer using the patient's own tissue (from the abdomen, back, or other sites) The choice depends on patient preference, body habitus, and surgical considerations. Treatment of Metastatic Disease Metastatic breast cancer is incurable but treatable. The goal of treatment is to prolong survival and maintain quality of life. Systemic therapy is the primary approach, and treatment selection depends heavily on molecular characteristics and prior therapy. Bone-Targeting Agents Breast cancer frequently metastasizes to bone. Bone-targeting agents such as denosumab (a RANKL inhibitor) and bisphosphonates reduce the risk of skeletal complications, including fractures and spinal cord compression. These agents are typically given every three months. Endocrine Therapy for Hormone-Receptor-Positive Metastatic Disease Hormone-receptor-positive metastatic disease remains responsive to endocrine therapy, often for extended periods. Treatment typically combines traditional endocrine agents with newer targeted therapies. CDK4/6 inhibitors (palbociclib, ribociclib, abemaciclib) block cyclin-dependent kinases involved in cell-cycle progression. When combined with endocrine therapy, CDK4/6 inhibitors significantly improve progression-free survival in hormone-receptor-positive metastatic disease. They may be combined with tamoxifen, aromatase inhibitors, or fulvestrant (a selective estrogen-receptor degrader). mTOR inhibitor everolimus can be added to certain endocrine regimens in patients who have progressed on prior therapies, providing additional benefit through inhibition of mTOR signaling, which promotes cell growth. HER2-Targeted Therapy for HER2-Positive Metastatic Disease HER2-positive metastatic disease continues to benefit from HER2-directed agents. Options include: Trastuzumab and pertuzumab continue from the early-stage setting and often remain effective in the metastatic setting. Antibody-drug conjugates (ADCs) attach cytotoxic chemotherapy to HER2-targeting antibodies, delivering chemotherapy directly to HER2-positive cancer cells: Trastuzumab emtansine combines trastuzumab with a microtubule inhibitor Trastuzumab deruxtecan combines trastuzumab with a topoisomerase inhibitor and has shown particularly strong efficacy HER2-directed tyrosine kinase inhibitors directly block HER2 signaling: Lapatinib inhibits both HER2 and EGFR Neratinib is a pan-HER inhibitor Tucatinib is a selective HER2 inhibitor often combined with trastuzumab and capecitabine (chemotherapy) Targeted Therapy Based on Specific Genetic Alterations Genomic testing of metastatic tumors identifies actionable mutations that guide targeted therapy beyond hormone-receptor and HER2 status. PIK3CA mutations (which activate phosphatidylinositol 3-kinase signaling) can be targeted with: Alpelisib, a selective PI3K inhibitor, combined with endocrine therapy Capivasertib, an AKT inhibitor BRCA1/BRCA2 mutations indicate defective DNA repair. These tumors are sensitive to: PARP inhibitors (olaparib, talazoparib), which prevent DNA repair and cause cell death in BRCA-mutated cancers DNA-repair deficiencies and related genomic instability can be exploited with: Immune checkpoint inhibitors, particularly pembrolizumab in tumors with high microsatellite instability or mismatch-repair deficiency Atezolizumab, an anti-PD-L1 checkpoint inhibitor, is used for PD-L1-positive metastatic tumors, especially triple-negative cancers <extrainfo> Note on triple-negative breast cancer: This subtype (negative for estrogen receptor, progesterone receptor, and HER2) lacks the targeted therapies available for hormone-receptor-positive and HER2-positive disease. Management relies on chemotherapy, immune checkpoint inhibitors (particularly in PD-L1-positive or DNA-repair-deficient tumors), and PARP inhibitors in BRCA-mutated cases. This explains why molecular subtype is so critical to treatment planning. </extrainfo> Key Principles for Treatment Selection The molecular subtype of the tumor—hormone-receptor and HER2 status—fundamentally shapes the treatment plan. Hormone-receptor-positive tumors benefit from endocrine therapy; HER2-positive tumors from HER2-targeted agents; and triple-negative tumors from chemotherapy and, in selected cases, checkpoint inhibitors or PARP inhibitors. In metastatic disease, additional genomic testing guides the selection of targeted therapies. Systemic therapy decisions also incorporate patient factors such as age, comorbidities, and functional status to balance treatment efficacy with tolerability.